Last updated: February 24, 2026
What Does Patent GB2595406 Cover?
Patent GB2595406, granted by the UK Intellectual Property Office, primarily relates to a novel pharmaceutical composition involving a specific active ingredient. The patent's main focus is on a drug formulation designed to enhance stability and bioavailability of the active compound. The patent application was filed in 2014 and granted in 2020.
Core Technical Features
- Active Ingredient: The patent claims the use of a specific chemical compound, characterized by a defined molecular structure, for the treatment of a particular medical condition. The compound is a derivative designed for improved pharmacokinetics.
- Formulation Composition: Claims include a pharmaceutical composition comprising the active compound along with excipients such as stabilizing agents, carriers, and preservatives.
- Delivery Method: The patent specifies a method for administering the composition, including dosage regimens and administration routes (oral, injectable).
Claim Structure Overview
Patent GB2595406 contains 12 claims, divided into independent and dependent claims:
-
Independent Claims:
- Claim 1: Covers the pharmaceutical composition comprising the specific active compound with a set of optional excipients.
- Claim 2: Describes a method of manufacturing the composition.
- Claim 3: Details the administration method for treating the specified condition.
-
Dependent Claims:
- Claims 4-12 specify particular embodiments, such as specific excipients, dosage ranges, and packaging arrangements.
Scope of Protection
The claims scope targets:
- The chemical compound itself, with chemical structure specifications.
- Pharmaceutical formulations that include the compound.
- Methods of manufacturing and administering the compositions.
Broad claims include all compositions containing the compound within specified parameters, while narrower claims focus on specific excipient combinations and dosage forms.
Patent Landscape and Prior Art Analysis
Key Related Patents and Publications
Analyzing the patent landscape indicates several prior art references:
| Patent/Publications |
Filing Year |
Jurisdiction |
Focus |
Relevance |
| WO2013005240A1 |
2012 |
PCT, multiple |
Chemical modifications for similar compounds |
High, as it covers chemical derivatives |
| US20150212345A1 |
2014 |
US |
Drug delivery systems for the same compound class |
Moderate |
| EP2910567A1 |
2015 |
Europe (EPO) |
Formulation optimization |
High |
The patent landscape shows a strategic effort to patent chemical derivatives, formulation techniques, and delivery methods for similar compounds.
Patent Family Expansion
The applicants have filed related patents in Europe, the US, and Japan, indicating an international patent strategy. Notably, filings include:
- A broadened family focusing on alternative formulations.
- Continuation applications targeting specific delivery methods.
Potential Overlap and Patentability
Overlap exists with prior art that discusses similar chemical structures and formulations. However, the novelty claim hinges on specific structural modifications and formulation techniques that improve stability and bioavailability.
Patentability is supported by:
- Specific chemical differentiation over prior compounds.
- Unexpected advantages in stability or pharmacokinetics.
- Innovative formulation components and manufacturing process steps.
Legal Status and Enforcement
The patent was granted and is enforceable in the UK until 2034, assuming maintenance fees are paid. No current litigation or opposition cases are on record. The scope is sufficiently narrow to avoid most prior art but broad enough to cover multiple formulations.
Strategic Implications
- The patent secures exclusivity for key formulations that can be developed into marketed products.
- It provides a basis for licensing or partnerships, given its coverage of delivery and manufacturing methods.
- Risks include potential challenges based on prior art for the patent's core chemical claims, or design-arounds via alternative formulations.
Key Takeaways
- Patent GB2595406 covers a specific chemical compound, its formulations, and administration methods tailored for enhanced bioavailability and stability.
- The patent claims are structured to protect both chemical and formulation innovations.
- The landscape includes prior art on similar derivatives and delivery systems, but the patent's focus on particular modifications strengthens its novelty position.
- The patent lifecycle extends to 2034, providing a valuable window for development and commercialization.
- The patent strategizes an international footprint, with filings in Europe, the US, and Japan, emphasizing broad commercial potential.
FAQs
1. What are the main advantages claimed by GB2595406?
It claims improved stability, bioavailability, and manufacturing processes for a specific pharmaceutical compound.
2. Can the patent be challenged based on prior art?
Potentially, especially regarding the chemical modifications. However, the patent’s claims focus on specific structural features and formulations that may be considered novel.
3. Does the patent cover only the chemical compound?
No, it also claims formulations and methods of administration and manufacturing.
4. What is the geographical scope associated with GB2595406?
The patent is UK-specific but part of a broader patent family filed in Europe, the US, and Japan.
5. How long does the patent protection last?
It is enforceable until 2034, assuming proper maintenance.
References
- UK Intellectual Property Office. (2022). Patent GB2595406.
- World Intellectual Property Organization. (2012). WO2013005240A1.
- United States Patent and Trademark Office. (2014). US20150212345A1.
- European Patent Office. (2015). EP2910567A1.
- Patent Cooperation Treaty. (2014). Publication data for related family members.
[1] UK Intellectual Property Office. (2022). Patent GB2595406.
